Berlan M, Galitzky J, Riviere D, Foureau M, Tran M A, Flores R, Louvet J P, Houin G, Lafontan M
Laboratoire de Pharmacologie Médicale et Clinique, INSERUM U-317, Faculté de Médecine, Toulouse, France.
Int J Obes. 1991 May;15(5):305-15.
Oral yohimbine administration (0.2 mg/kg) induced lipid mobilization (increase in plasma non-esterified fatty acids, NEFA) in fasting non-obese women (body mass index BMI = 20.2 +/- 0.5, age 35.5 +/- 2.7 years) without significant action on plasma glucose, insulin levels, heart rate or blood pressure during the time-course of the experiment (240 min). Plasma norpinephrine (but not epinephrine) concentrations were increased (100 percent) after oral yohimbine administration. Oral administration of propranolol (40 mg, 60 min before yohimbine) reduced the lipid-mobilizing action of yohimbine (70 percent) during the 60 min following its administration and then totally suppressed its effect until the end of the experimental period (180 min). In fasting obese women (BMI = 36.4 +/- 2.1, age 37 +/- 3.6 years), yohimbine provoked an increase in plasma NEFA levels which was not markedly different from that observed in non-obese subjects. It had no significant effect on plasma glucose, insulin levels, heart rate or blood pressure. Plasma norepinephrine increased in the same proportions. The lipid-mobilizing effect of yohimbine in women is mainly attributable to the increase in synaptic norepinephrine with a resultant increment in lipolysis by beta-adrenergic agonism. In the standard fasting conditions (12 hours) the blockade of the antilipolytic fat cell alpha 2-adrenoceptors seems to be a minor component of the lipomobilizing effect of yohimbine. Morever, when compared with non-obese women, the lipomobilizing effect of yohimbine is not enhanced in obese women.
口服育亨宾(0.2毫克/千克)可诱导空腹非肥胖女性(体重指数BMI = 20.2±0.5,年龄35.5±2.7岁)的脂质动员(血浆非酯化脂肪酸,NEFA增加),在实验过程(240分钟)中对血浆葡萄糖、胰岛素水平、心率或血压无显著影响。口服育亨宾后,血浆去甲肾上腺素(而非肾上腺素)浓度升高(100%)。口服普萘洛尔(40毫克,在育亨宾前60分钟)可在育亨宾给药后的60分钟内降低其脂质动员作用(70%),然后在实验期结束(180分钟)前完全抑制其作用。在空腹肥胖女性(BMI = 36.4±2.1,年龄37±3.6岁)中,育亨宾引起血浆NEFA水平升高,与非肥胖受试者中观察到的情况无明显差异。它对血浆葡萄糖、胰岛素水平、心率或血压无显著影响。血浆去甲肾上腺素以相同比例增加。育亨宾在女性中的脂质动员作用主要归因于突触去甲肾上腺素的增加,从而通过β-肾上腺素能激动作用增加脂肪分解。在标准空腹条件(12小时)下,抗脂解脂肪细胞α2-肾上腺素能受体的阻断似乎是育亨宾脂质动员作用的次要组成部分。此外,与非肥胖女性相比,育亨宾在肥胖女性中的脂质动员作用并未增强。